arrow
P

Pilar Escribano Subías

hospital universitario 12 de octubre
H指数:36
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Partial Echocardiographic Remission After Sotatercept: Expanding Treatment Goals in Pulmonary Arterial Hypertension

sotatercept治疗后部分超声心动图缓解:扩展肺动脉高压的治疗目标

2026-10-190
PRE
Surviving Males With PORCN Variants: Expanding the Clinical, Molecular, and Mechanistic Spectrum

携带PORCN变异的男性存活者:扩展临床、分子和机制谱

2026-09-260
OAAI
The added value of echocardiography in pulmonary arterial hypertension risk assessment an artificial intelligence machine learning–derived analysis of the ULTRA RIGHT VALUE registry

超声心动图在肺动脉高压风险评估中的附加价值:一项基于人工智能机器学习的ULTRA RIGHT VALUE注册研究分析

2026-09-170
OAAI
Balancing Risk and Hope: Insights Into Pregnancy Outcomes in Pulmonary Arterial Hypertension

权衡风险与希望:对肺动脉高压妊娠结局的洞察

2026-05-240
PREAI
Chronic thromboembolic pulmonary disease with exercise pulmonary hypertension – A non-invasive model to predict exercise hemodynamics

慢性血栓栓塞性肺病伴运动性肺动脉高压——一种预测运动血流动力学的无创模型

CHEST
IF8.6
2025-11-120
PRE
Real-life use of validated quality of life questionnaires in patients with pulmonary arterial hypertension in Spain: a cross-sectional study

在西班牙肺动脉高压患者中使用经过验证的生活质量问卷的实际情况:一项横断面研究

2025-09-010
OAAI
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Seralutinib治疗成人肺动脉高压:TORREY开放标签扩展研究

2025-08-110
OA
Comparison of Tricuspid Annular Plane Systolic Excursion to Pulmonary Artery Systolic Pressure Ratio Measured by Transthoracic Echocardiography and Right Heart Catheterization in Pulmonary Arterial Hypertension: Prognostic Implications
2025-03-140
OAAI
Late Breaking Abstract- Assessing the Clinical Benefit, Safety, and Patient-reported Outcomes with the Use of the PAHcareTM Digital Platform in Pulmonary Arterial Hypertension: A Pilot Study.
2024-10-300
PRE
Management of Pulmonary Hypertension associated with Chronic Lung Disease: Results of the ERS Clinical Research Collaboration PHAROS survey

与慢性肺部疾病相关的肺动脉高压的管理: ERS临床研究合作PHAROS调查的结果

2024-10-300
PRE
Sustained benefit with seralutinib treatment: Lessons from the open-label extension (OLE) of the TORREY study
2024-10-300
PRE